Medicina · Nov 18, 2026

Intra-Procedural and 24-Hour Safety of Physician-Supervised Outpatient Intravenous Micronutrient and Coenzyme Therapy: A Real-World Retrospective Study of 1433 Infusion Procedures in 155 Adults

By Micarelli A, Mrakic-Sposta S, Malacrida S et al.

Background and Objectives: Physician-supervised outpatient intravenous micronutrient therapy (IVMT) is increasingly used, yet procedure-level safety data from real-world practice remain scarce. This study aimed to characterize, at the procedure level, the adverse events occurring during individualized micronutrient and coenzyme infusions and within the subsequent 24 h. Materials and Methods: We conducted a retrospective single-centre cohort study of 155 consecutive adults who underwent 1433 peripheral intravenous infusion procedures between January and October 2025. Adverse events (AEs) occurring during the procedure or within 24 h were classified by category, severity, and timing (post-discharge ascertainment was passive); the 95% confidence interval (CI) of the overall rate accounted for within-patient clustering. Exploratory secondary outcomes were paired pre–post changes in SF-36 (RAND-36) domains and in a 36-analyte laboratory panel. Results: At least one AE was documented in 220 procedures (15.4%; 95% CI 12.4–18.5) and in 99 patients (63.9%). All events were mild (n = 106) or moderate (n = 114); no severe or serious AEs, emergency department referrals, or hospitalizations were documented. Procedural/access-related events were the most frequent category (6.1% of procedures). NAD+ monotherapy showed the highest crude AE frequency (65/76 sessions, 85.5%, mostly moderate; 29.5% of all AEs from 5.3% of procedures), compared with 11.4% for all other formulations combined. Seven of eight SF-36 domains and 24 of 36 laboratory analytes changed significantly after false discovery rate correction. Conclusions: In this cohort, physician-supervised outpatient IVMT was associated with frequent but exclusively mild-to-moderate, mostly intra-procedural AEs, whose documented frequency likely underestimates the true frequency. NAD+ infusions accounted for a disproportionate share; the study does not identify a safe dose or infusion rate, and cautious titration, close observation, and dedicated informed consent appear warranted. The secondary findings are hypothesis-generating and require confirmation in controlled prospective studies.

doi.org/10.3390/medicina62112263Open accessInterventions

AgingResearch.News